AZD-9164

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C29H38FN2O2
Molecular Weight	465.6226
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	1

SHOW SMILES / InChI

SMILES

C[C@@](N1CCCCC1)(C(=O)O[C@H]2C[N+]4(CCC3=CC=C(F)C=C3)CCC2CC4)C5=CC=CC=C5

InChI

InChIKey=FNYFFCOCVNTJCD-NNMXADRKSA-N

InChI=1S/C29H38FN2O2/c1-29(25-8-4-2-5-9-25,31-17-6-3-7-18-31)28(33)34-27-22-32(20-15-24(27)16-21-32)19-14-23-10-12-26(30)13-11-23/h2,4-5,8-13,24,27H,3,6-7,14-22H2,1H3/q+1/t24?,27-,29-,32?/m0/s1

HIDE SMILES / InChI

Molecular Formula	C29H38FN2O2
Molecular Weight	465.6226
Charge	1
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	EPIMERIC
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description

AZD9164 was invented by AstraZeneca as a muscarinic M(3) receptor antagonist for evaluation of the potential as a treatment for chronic obstructive pulmonary disease. However, in 2010 studies were discontinued.

Originator

Approval Year

PubMed

PubMed

Title	Date	PubMed
The discovery of AZD9164, a novel muscarinic M3 antagonist.	2011 Dec 15	22047691

Sample Use Guides

In Vivo Use Guide

Solution for inhalation through nebulization, single dose. AZD9164 solution for inhalation through nebulisation 100 mcg (lung deposited dose) + 1 x placebo for Spiriva dry powder for inhalation

Route of Administration: Other

Substance Class	Chemical
Record UNII	977LWC4O5D
Record Status	`Validated (UNII)`
Record Version

Show entries

Name

Type

Language

AZD-9164

Common Name

English

AZD9164

Code

English

AZD 9164 [WHO-DD]

Common Name

English

J3.232.015E

Code

English

1-AZONIABICYCLO(2.2.2)OCTANE, 1-(2-(4-FLUOROPHENYL)ETHYL)-3-((2S)-1-OXO-2-PHENYL-2-(1-PIPERIDINYL)PROPOXY)-, (3R)-

Systematic Name

English

Showing 1 to 5 of 6 entries

Previous1 2Next

Show entries

Code System

Code

Type

Description

CAS

1034978-04-5

PRIMARY

PUBCHEM

44517831

PRIMARY

FDA UNII

977LWC4O5D

PRIMARY

DRUG BANK

DB12115

PRIMARY

Showing 1 to 4 of 4 entries

Previous1Next

Show entries

Related Record

Type

Details


					AQ25R8YQ5Z

AZD-9164 BROMIDE

SALT/SOLVATE -> PARENT

Showing 1 to 1 of 1 entries

Previous1Next

Show entries

Related Record

Type

Details


					977LWC4O5D

AZD-9164

ACTIVE MOIETY

Comments:

Originator: AstraZeneca; Mechanism of Action: Muscarinic receptor antagonist; Highest Development Phase: Discontinued for Chronic obstructive pulmonary disease; Most Recent Events: 29 Jun 2010 Discontinued - Phase-II for Chronic obstructive pulmonary disease in Sweden (Inhalation), 28 Jun 2010 AtraZeneca terminates phase I trial (NCT01016951) in Chronic obstructive pulmonary disease in Sweden as one of the stopping criterion was met, 30 Jun 2009 Phase-II clinical trials in Chronic obstructive pulmonary disease in Sweden (Inhalation)

Showing 1 to 1 of 1 entries

Previous1Next